Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
You may also be interested in...
Bristol Drops Virology Discovery In Latest R&D Reshuffling
Firm plans to expand presence in Boston and San Francisco, while shuttering or de-emphasizing other locations, and to end virology discovery, in line with R&D strategy introduced in 2013.
Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss
Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.
Bristol’s Virology Focus Turning To Hepatitis B? An Interview With Doug Manion
At the AASLD conference, Bristol talked up its filing of a two-drug oral combination to treat hepatitis C in Japan, which would be the first oral combo regimen to reach market for the virus. But with plans to end discovery research in HCV, will the pharma focus its virology efforts more on hepatitis B and HIV?